Raji In Vitro Post-translational Modifications Assay
CAT#: ITS-1022-YF2614
Target Cell Organism: Human
Target Cell Name: Raji
Assay Type: Gene and Protein Expression Assays
Assay Overview
This assay is to provide Raji-based In Vitro Post-translational Modifications Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
Raji
Target Cell Organism
Human
Target Cell Background
Raji cells were derived from the B-lymphocytes of an 11-year-old Nigerian Burkitt's lymphoma male patient in 1963 by R.J.V. Pulvertaft and was further worked on by B.O. Osunkoya (University College Hospital, Ibadan, Nigeria). The Raji cell line is categorized as lymphoblast-like.
Related Diseases
B Lymphoma
Research Area
Oncology
Assay Name
In Vitro Post-translational Modifications Assay
Short Description
Raji-cell based In Vitro Post-translational Modifications Assay
Assay Description
Immunoassays and mass spectrometry techniques are considered ideal techniques for the detection of post-translational modification. Both the genetic and epigenetic modifications have contributed to the initiation and progression of cancer.
Assay Type
Gene and Protein Expression Assays
Assay Type Details
Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.